MyMyelomaTeam

Yes, EMP (extramedullary plasmacytoma) is indeed a very rare condition, affecting fewer than 1 in 500,000 people. While radiation therapy and surgery are typically the standard first-line treatments with success rates around 90%, recurrence can happen as you've experienced. To diagnose EMP and distinguish it from multiple Show Full Answer

Yes, EMP (extramedullary plasmacytoma) is indeed a very rare condition, affecting fewer than 1 in 500,000 people. While radiation therapy and surgery are typically the standard first-line treatments with success rates around 90%, recurrence can happen as you've experienced. To diagnose EMP and distinguish it from multiple myeloma (MM), doctors look for the absence of CRAB features (Calcium elevation, Renal failure, Anemia, Bone lesions) and confirm that there are less than 5% plasma cells in the bone marrow. About 10-30% of EMP cases can eventually develop into multiple myeloma, which is why ongoing monitoring and adjusted treatment plans are important. Your current treatment combination of Dara (Daratumumab), Bortezomib, and Dex (Dexamethasone) is a recognized approach for managing recurrent disease. While chemotherapy isn't typically used as first-line treatment for initial EMP, it may be necessary for recurrent cases.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Extramedullary Plasmacytoma: Your Guide